title: Gene expression analysis in sinonasal polyposis before and after oral corticosteroids: a preliminary investigation.
abstract: OBJECTIVE
  To characterize gene expression in sinonasal polyps and to gain insight into change in expression after oral corticosteroid treatment.
  
  
  METHODS
  Nasal polyps were obtained before and after oral corticosteroid treatment and gene expression was analyzed with a focused gene array technique.
  
  
  RESULTS
  Pretreated sinonasal polyps demonstrated high gene expression for chemokine and leukotriene receptor genes (CCR2, CCR5, CX3CL1, and LTB4R) in all patients. After treatment, the global effects of corticosteroids were evident on gene expression.
  
  
  CONCLUSIONS
  Gene array techniques hold promise as a research method in sinonasal polyposis. The potential benefits, as well as the potential challenges, in using these research methods will be discussed.
authors.affiliation: Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD 20817, USA. sinusmd@comcast.net
authors.forename: William E
authors.initials: WE
authors.lastname: Bolger
authors.forename: Arjun S
authors.initials: AS
authors.lastname: Joshi
authors.forename: Samuel
authors.initials: S
authors.lastname: Spear
authors.forename: Michael
authors.initials: M
authors.lastname: Nelson
authors.forename: Krishnamurthy
authors.initials: K
authors.lastname: Govindaraj
mesh_terms: D000284:Administration, Oral; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001706:Biopsy; D018932:Chemokine CCL2 / Q000187:drug effects / Q000235:genetics; D054428:Chemokine CX3CL1; D020523:Chemokines, CX3C / Q000235:genetics; D015536:Down-Regulation / Q000235:genetics; D004724:Endoscopy; D005260:Female; D015870:Gene Expression / Q000235:genetics*; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007975:Leukotriene B4 / Q000235:genetics; D008297:Male; D008565:Membrane Proteins / Q000187:drug effects / Q000235:genetics; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use*; D009298:Nasal Polyps / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D020411:Oligonucleotide Array Sequence Analysis; D010254:Paranasal Sinus Diseases / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D011127:Polyps / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D054390:Receptors, CCR2; D019713:Receptors, CCR5 / Q000187:drug effects / Q000235:genetics; D019707:Receptors, Chemokine / Q000187:drug effects / Q000235:genetics; D018102:Receptors, Leukotriene B4 / Q000187:drug effects / Q000235:genetics
chemical_list: D000893:Anti-Inflammatory Agents; C515334:CCR2 protein, human; C515538:CX3CL1 protein, human; D018932:Chemokine CCL2; D054428:Chemokine CX3CL1; D020523:Chemokines, CX3C; D005938:Glucocorticoids; C513240:LTB4R protein, human; D008565:Membrane Proteins; D054390:Receptors, CCR2; D019713:Receptors, CCR5; D019707:Receptors, Chemokine; D018102:Receptors, Leukotriene B4; D007975:Leukotriene B4; D008775:Methylprednisolone